In a new study, they investigated one of the lncRNA MaTAR25 (Mammary Tumor Associated RNA 25). The results showed that knocking out MaTAR25 would reduce the proliferation, migration and invasion of cancer cells. Moreover, the increased expression of the human ortholog of MaTAR25, LINC01271, is associated with poor prognosis and poor metastasis.
Cancer is not a kind of disease, but a name for a group of related diseases characterized by mutations or other changes in the genome that cause uncontrolled cell growth. Tumors can have hundreds to thousands of mutations, but only a few are critical to their tumorigenic ability. These key mutations affect the function of cancer driver genes. Finding genes with such cancer driver mutations is one of the main goals of cancer research.
Recently, the New England Journal of Medicine published the results of a double-blind, randomized, placebo-controlled trial ACTT-2 of the antiviral drug remdesivir and the anti-inflammatory drug Baricitinib in the treatment of COVID-19. This combination therapy can shorten the recovery time of COVID-19 hospitalized patients.
On December 2, 2020, Pfizer and BioNTech announced that the British Medicines & Healthcare Products Regulatory Agency (MHRA) granted a temporary authorization for their COVID-19 mRNA vaccine (BNT162b2) against for COVID-19. It is the first country in the world to be granted emergency use authorization for BNT162b2.
Recently, the results of the secondary analysis of VITAL research data were published in JAMA Network Open, a subsidiary of the Journal of the American Medical Association. Data shows that taking vitamin D is associated with a lower overall risk of developing advanced (metastatic or fatal) cancer, and weight can affect the association between them.
In December 2005, it was approved by the FDA as a first-line drug for the treatment of advanced kidney cancer. This is the only targeted drug approved by the FDA for the treatment of kidney cancer in the past 10 years, and it is a major progress in the treatment of kidney cancer. Sorafenib is the world's first approved multi-target anti-cancer drug.
Researchers discovered a new immune defense mechanism that is unknown so far. It is a mechanism orchestrated by lipid droplets (LDs), the cellular organelles can attract and eliminate invading pathogens.
Recently, the team of Professor Jin Hongjun from the Molecular Imaging Center of Sun Yat-sen University No.5 Hospital and the Tumor Center of Sun Yat-sen University No.5 Hospital explored a novel method to improve hypoxia in photodynamic therapy, and preliminarily found that oxyphotodynamic therapy combined with metformin has the potential to treat triple-negative breast cancer.